Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
NRIX | US
0.23
1.05%
Healthcare
Biotechnology
31/05/2024
04/10/2024
22.20
21.86
23.12
21.86
Nurix Therapeutics Inc. a clinical stage biopharmaceutical company focuses on the discovery development and commercialization of small molecule and cell therapies for the treatment of cancer and other diseases. The company develops NX-2127 an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948 an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607 an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications. It is also developing DeTIL-0255 a drug-enhanced investigational cell therapy product that uses NX-0255 ex vivo to enhance tumor infiltrating lymphocytes propagation and phenotypic characteristics. The company has a strategic collaboration agreement with Gilead Sciences Inc. to discover develop and commercialize a pipeline of protein degradation drugs for patients with cancer and other challenging diseases; and Sanofi S.A. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics Inc. in October 2018. The company was incorporated in 2009 and is headquartered in San Francisco California.
View LessLow Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Strong Sharpe Ratio (> 1.2)
Price Below SMA10D
High 6-Month Volatility (>65%)
Smallcap (300M - 2B USD)
High Market Beta (> 0.8)
High Short percentage (> 15%)
Weak Operating Margin (< 10%)
Declining Revenue (< 0%)
Bearish: Increased Volatility (6-month > 1-month volatility)
10 days
37.2%1 month
42.0%3 months
54.5%6 months
80.6%-
-
4.01
0.08
0.06
-3.35
17.18
-
-172.24M
1.43B
1.43B
-
-401.42
-
-60.60
-52.33
19.32
15.71
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
Range10D
4.46
Range1M
5.01
Range3M
8.68
Rel. volume
0.74
Price X volume
9.67M
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
BioCryst Pharmaceuticals Inc | BCRX | Biotechnology | 7.58 | 1.57B | 2.71% | n/a | -178.85% |
Belite Bio Inc | BLTE | Biotechnology | 50.99 | 1.56B | 4.68% | n/a | 0.00% |
Immunocore Holdings plc | IMCR | Biotechnology | 31.11 | 1.56B | 0.06% | n/a | 131.69% |
Ocular Therapeutix Inc | OCUL | Biotechnology | 9.84 | 1.53B | 5.69% | n/a | 19.83% |
Arcus Biosciences Inc | RCUS | Biotechnology | 16.65 | 1.52B | 8.19% | n/a | 1.73% |
Rocket Pharmaceuticals Inc | RCKT | Biotechnology | 16.41 | 1.49B | -3.24% | n/a | 6.71% |
IRON | IRON | Biotechnology | 49.93 | 1.48B | -2.48% | n/a | 0.38% |
Cassava Sciences Inc | SAVA | Biotechnology | 27.08 | 1.45B | 0.52% | n/a | 0.00% |
Dynavax Technologies Corporation | DVAX | Biotechnology | 11.02 | 1.44B | -2.91% | 84.62 | 39.71% |
Longboard Pharmaceuticals Inc. Common Stock | LBPH | Biotechnology | 36.22 | 1.41B | -0.55% | n/a | 1.31% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Steelcase Inc | SCS | Building Products & Equipment | 12.97 | 1.47B | 0.78% | 12.50 | 65.47% |
REV Group Inc | REVG | Recreational Vehicles | 27.56 | 1.43B | 0.00% | 6.15 | 63.13% |
Janus International Group Inc. | JBI | Building Products & Equipment | 9.79 | 1.42B | 2.73% | 11.54 | 116.21% |
Pitney Bowes Inc | PBI | Building Products & Equipment | 6.92 | 1.24B | 1.91% | n/a | -571.93% |
ARLO TECHNOLOGIES INC | ARLO | Building Products & Equipment | 11.47 | 1.15B | 0.09% | n/a | 19.46% |
Camping World Holdings Inc | CWH | Recreational Vehicles | 23.44 | 1.06B | -0.38% | n/a | 3644.76% |
Malibu Boats Inc | MBUU | Recreational Vehicles | 39.7 | 793.63M | -0.68% | n/a | 1.50% |
Latham Group Inc. | SWIM | Building Products & Equipment | 6.64 | 767.43M | 0.00% | 61.27 | 77.00% |
Ennis Inc | EBF | Building Products & Equipment | 24.31 | 631.67M | 2.36% | 15.15 | 2.42% |
ACCO Brands Corporation | ACCO | Building Products & Equipment | 5.25 | 502.94M | -0.19% | n/a | 174.23% |
Parameter | Company | Industry | Indicator |
---|---|---|---|
Enterprise to EBITDA | -3.35 | 0.76 | Cheaper |
Ent. to Revenue | 17.18 | 3,674.48 | Cheaper |
PE Ratio | - | 38.01 | - |
Price to Book | 4.01 | 14.10 | Cheaper |
Dividend Yield | - | 2.22 | - |
Std. Deviation (3M) | 54.48 | 74.67 | Lower Risk |
Debt to Equity | 0.08 | -1.82 | Expensive |
Debt to Assets | 0.06 | 0.26 | Cheaper |
Market Cap | 1.43B | 3.73B | Emerging |